Company profile: Respicardia
1.1 - Company Overview
Company description
- Provider of implantable therapies to improve respiratory rhythm management and cardiovascular health, including the FDA-approved remedē System for adults with moderate to severe Central Sleep Apnea (CSA) to restore normal breathing during sleep, and the remedē Patient Pathway offering resources for screening, selection, implant, optimization, and follow-up.
Products and services
- Implantable Therapies for Respiratory and Cardiovascular Health: Engineers implantable therapies designed to improve respiratory rhythm management and cardiovascular health for heart failure patients
- Remedē Patient Pathway: Delivers a device-specific educational service with resources for screening, patient selection, device implant, therapy optimization, and follow-up for the remedē System
- Remedē System: FDA-approved implantable stimulation device for adults with moderate to severe Central Sleep Apnea (CSA), restores normal breathing during sleep without masks or medication
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Respicardia
CinCor Pharma
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cardiovascular, metabolic, and kidney diseases, advancing promising clinical candidates toward marketing approval, including CIN-107, a novel aldosterone synthase inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CinCor Pharma company profile →
BTG
HQ: United Kingdom
Website
- Description: Provider of interventional medicine, pharmaceuticals, and licensing solutions, acquiring, developing, manufacturing, and commercializing products globally. Interventional oncology offerings include beads and TheraSphere Y-90 Glass Microspheres for HCC; other devices include Jetstream Atherectomy System, Vercise Genus DBS, Varithena 1% foam, WaveWriter Alpha SCS, and AcuPulse DUO CO2 Laser.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BTG company profile →
Ridgeback Technologies
HQ: Ireland
Website
- Description: Provider of advanced catheter balloons, specializing in the design, development, and manufacture for various medical applications. Offers perfusion balloons with a figure-of-eight cross section that maintains shape across pressure ranges to allow partial vessel flow, and custom balloons with tailored materials, sizes, and pressure specifications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ridgeback Technologies company profile →
Preventice Solutions
HQ: United States
Website
- Description: Provider of mobile cardiac health solutions and remote monitoring services, connecting patients, clinicians, and hospitals. Offerings include BodyGuardian wearable waterproof ECG monitors and BodyGuardian MINI PLUS for mobile cardiac telemetry; the HIPAA-compliant PatientCare platform for near-real-time data management; and service models from full-service monitoring to equipment and software purchase options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Preventice Solutions company profile →
Essential Medical
HQ: United States
Website
- Description: Provider of femoral artery closure devices to seal femoral punctures following vascular access medical procedures requiring a cardiac catheterization. The company has developed two devices, including MANTA, designed to close large-bore punctures (10–24F) after procedures such as transcatheter aortic valve replacement (TAVR) and abdominal aortic aneurysm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Essential Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Respicardia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Respicardia
2.2 - Growth funds investing in similar companies to Respicardia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Respicardia
4.2 - Public trading comparable groups for Respicardia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →